Skip to Content
Merck
  • Structure-activity relationship studies of G9a-like protein (GLP) inhibitors.

Structure-activity relationship studies of G9a-like protein (GLP) inhibitors.

Bioorganic & medicinal chemistry (2017-07-01)
Yan Xiong, Fengling Li, Nicolas Babault, Hong Wu, Aiping Dong, Hong Zeng, Xin Chen, Cheryl H Arrowsmith, Peter J Brown, Jing Liu, Masoud Vedadi, Jian Jin
ABSTRACT

Given the high homology between the protein lysine methyltransferases G9a-like protein (GLP) and G9a, it has been challenging to develop potent and selective inhibitors for either enzyme. Recently, we reported two quinazoline compounds, MS0124 and MS012, as GLP selective inhibitors. To further investigate the structure-activity relationships (SAR) of the quinazoline scaffold, we designed and synthesized a range of analogs bearing different 2-amino substitutions and evaluated their inhibition potencies against both GLP and G9a. These studies led to the identification of two new GLP selective inhibitors, 13 (MS3748) and 17 (MS3745), with 59- and 65-fold higher potency for GLP over G9a, which were confirmed by isothermal titration calorimetry (ITC). Crystal structures of GLP and G9a in complex with 13 and 17 provide insight into the interactions of the inhibitors with both proteins. In addition, we generated GLP selective inhibitors bearing a quinoline core instead of the quinazoline core.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MS012, ≥98% (HPLC)